/index.php?option=com_iwpfile&file=/dir_01/he2002_1886.pdf


ts

July 12, 2002

Contact: Patricia Nemore, CMA

202-216-0028

Deane Beebe, MRC

212-204-6219

HEALTH CARE CONSUMER GROUP SUES FEDERAL DEPARTMENT FOR RELEASE OF INFORMATION Click here for Complaint



/index.php?option=com_iwpfile&file=/dir_01/he2002_1883.pdf


es

FOR IMMEDIATE RELEASE:

Thursday, July 11, 2002

CONTACT: Ken Johnson or Peter Sheffield

202-225-5735

Tauzin, Greenwood Want Details From FDA on Breast Implant Studies

Washington (July 11) - In light of reported concerns about the safety of saline breast implants, House Energy and Commerce Committee Chairman Billy Tauzin (R-LA) and Oversight and Investigations Subcommittee Chairman James Greenwood (R-PA) today called on the Food and Drug Administration (FDA) to turn over records relating to implant studies.



ll

Solely in the case of drug products for which the analytical methods described in subparagraphs (A) and (B) cannot be applied, because such drug products have been demonstrated not to rely primarily on systemic absorption to achieve their effectiveness, bioavailability and bioequivalence may be based on other types of evidence, as prescribed by regulation promulgated by the Secretary.

BIO's Primary Concerns on Redraft of S. 812

Sec. 8 - Bioequivalence



nd

PhRMA opposes the drug patents reform bill passed by the Senate Health Committee today, July 11, and charges that the bill is too complex for the senators to comprehend. PhRMA-Edwards/Kennedy PhRMA Statement



107th CONGRESS
S.


/index.php?option=com_iwpfile&file=/dir_01/he2002_1876.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1877.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1878.pdf


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.